PDCD1 and melanoma: CX3CR1hi CD8+ T cells in PB are known to be increased after PD-1 inhibitor treatment in patients with melanoma and renal cell carcinoma51,52, and CX3CR1hi CD8+ T cells play a critical role in tumor eradication in vivo52.